Moberg Pharma AB MOB
OMXSTO · Sweden · Health Technology
SEK 11.00-0.30 (-2.65%)
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · SEK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®.
Karo Healthcare AB ("Karo") has entered an exclusive licensing agreement with Moberg Pharma AB ("Moberg Pharma") regarding the commercialisation of MOB-015 in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key European markets under the leading global antifungal brand Lamisil®1.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.